Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00304083 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors
A Phase 2 study of Sarcoma and Neurofibromatosis Type 1, sponsored by Sarcoma Alliance for Research through Collaboration.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 17
- Study locations
NCT00304083: Completed Phase 2 study of Sarcoma and Neurofibromatosis Type 1, sponsored by Sarcoma Alliance for Research through Collaboration.
NCT00304083 is a Phase 2 study of Sarcoma and Neurofibromatosis Type 1 that has completed, run by Sarcoma Alliance for Research through Collaboration. The registered enrollment target is 48 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (95% lower). The trial reports 17 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00304083, a Phase 2 study of Sarcoma and Neurofibromatosis Type 1, has completed, sponsored by Sarcoma Alliance for Research through Collaboration.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 17
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy with or without radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving combination chemotherapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating patients with stage III or stage IV malignant peripheral nerve sheath tumors.
Primary Outcome
WHO criteria was used to determine responses due to the nonspherical shape of most MPNST. Complete Response (CR), Disappearance of all target lesions; Partial response (PR), \>=50% decrease of target lesions.
Conditions Studied
Interventions
- DRUG etoposide
- PROCEDURE conventional surgery
- DRUG ifosfamide
- BIOLOGICAL filgrastim
- DRUG doxorubicin hydrochloride
Study Locations (17)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- Pennsylvania Oncology Hematology Associates - Philadelphia
- Children's Hospital of Pittsburgh - Pittsburgh
Maryland
- Johns Hopkins - Baltimore
- Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office - Bethesda
Alabama
- UAB Comprehensive Cancer Center - Birmingham
California
- Sarcoma Oncology Center - Santa Monica
Illinois
- Children's Memorial Hospital - Chicago - Chicago
Indiana
- Indiana University - Indianapolis
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2005-12 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
What the finished NCT00304083 record still lists
NCT00304083 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Sarcoma appearing as the primary indexed condition, and to 5 interventions - of which etoposide is the first listed.
NCT00304083 lists 17 locations in 14 states (Pennsylvania, Maryland, Alabama).
Frequently Asked Questions
What is clinical trial NCT00304083 about?
NCT00304083 is a clinical study titled "Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors". RATIONALE: Drugs used in chemotherapy, such as doxorubicin, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemothera...
What is the current status of trial NCT00304083?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2005-12. Estimated completion is 2014-06.
What conditions does trial NCT00304083 study?
This clinical trial studies the following conditions: Sarcoma, Neurofibromatosis Type 1.
What interventions are being tested in trial NCT00304083?
The interventions under investigation include: etoposide (DRUG), conventional surgery (PROCEDURE), ifosfamide (DRUG), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00304083?
This trial is sponsored by Sarcoma Alliance for Research through Collaboration, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00304083 being conducted?
This trial has 17 study locations across Alabama, California, Illinois, Indiana, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00304083's enrollment target sits among peer trials
48 70th of 122 higher than 53 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
RECRUITING · Phase 2
-
Fluorescent Intra-operative Tumor Margin Examination
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia